“Global primary cell culture market revenue is expected to reach $1.80 billion by 2029 at a CAGR of 8.7%”, says Visiongain

08 January 2020
Pharma

Visiongain’s new report the Primary Cell Culture Market Report: Forecasts by Origin (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, Renal Cells, Muscle Cells, Other Cells), by Type (Human, Animal), by End User (Life Science Research Companies, Research Institutes), plus analysis of leading companies operating in the global primary cell culture market.

Fewer chances of mutations and modifications, reducing testing cost, growing production of regenerative medicines, rising research & development in biotechnology and increasing demand for stem cell therapy is expected to drive global primary cell culture market over the projected period. In 2019, global primary cell culture market revenue was valued at $779 million and is expected to reach $1.80 billion by 2029 at a CAGR of 8.7%. Other major factors driving the growth of primary cell culture market are growing prevalence of cancer and other chronic diseases all over the world. According to the National Cancer Institute, in 2018, more than 1.5 million new cases of cancer were diagnosed in the United States and more than 600k people died from cancer.

The drain of chronic diseases is rapidly increasing worldwide. According to the World Health Organization, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. The proportion of the burden of chronic diseases is expected to increase to 57% by 2020. This, in turn, is expected to propel the primary cell culture industry over the coming years.

By region, North America dominated the global primary cell culture industry in 2019 and is expected to grow by virtue of technological advancement followed by well-developed healthcare infrastructure. Additionally, development and introduction of cell culture technologies coupled with increasing adoption of advanced therapies in Canada, the United States, and Mexico are expected to help market expansion over the coming years. Moreover, hectic lifestyle, increasing working hours, increasing working population, and consumer trends towards unhealthy foods has increased prevalence of chronic diseases in this region, which is expected to encourage primary cell culture industry over the projected period.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever